Table 3.

An overview of major ongoing trials of aspirin (status: April 2011)

TitleIdentifierPatientsInterventionsAspirin doseDesign/phaseStart dateEnd datePrimary outcomeFollow-up
Phase IIA Clinical Biomarker Trial of Aspirin and Arginine Restriction in Colorectal Cancer PatientsNCT00578721Resected CRCAspirin/arginine restriction325 mg/dPhase IISeptember 2008December 2012Change in markers (putrescine) of polyamine reduction3 y
Spectral Markers in Aspirin Chemoprevention of Colonic NeoplasiaNCT00468910History of CRC/adenomasAspirin325 mg/dPhase II, RCTMarch 2007April 2014Change in spectral slope and fractal dimension in rectal biopsies3 mo
Randomized Phase II Trial of Aspirin and Difluoromethylornithine (DFMO) in Patients at High Risk of Colorectal CancerNCT00983580History of CRC/adenomasAspirin and difluoromethy loorithine325 mg/dPhase II, RCTAugust 2009June 2015Adenoma recurrence rate1 y
The Systematic Evaluation of Aspirin and Fish Oil polyp prevention (SeAFOod)SRCTN05926847High-risk colorectal adenoma patientsAspirin and eicosapen- taenoic acid-free fatty acid300 mg/dPhase III, RCTSeptember 2011October 2014Number of colorectal adenomas1–3 y
Japan Colorectal Aspirin Polyps Prevention (J-CAPP)UMIN000000697Resected CRCAspirin100 mg/dPhase III, RCTJanuary 2007December 2012Newly developed tumors2–3 y
Aspirin for Dukes C and High Risk Dukes B Colon Cancer–An International, Multi-Centre, Double-blind, Randomised, Placebo-controlled, Phase III trial (ASCOLT)NCT00565708Dukes B, C colon or rectal cancerAspirin200 mg/dPhase III, RCTDecember 2008December 2019Disease-free survival5 y
Aspirin in Reducing Events in the Elderly (ASPREE)NCT01038583Aged ≥70 yearsAspirin 100 mg daily100 mg/dPhase III, RCTJanuary 2010August 2016Any cause mortality, dementia, or persistent physical disabilityEvery 3–6 mo
Aspirin to Reduce Risk of Initial Vascular Events (ARRIVE)NCT00501059Males aged ≥ 55 years with 2 cardiac risk factors and females ≥ 60 years with 3 cardiac risk factorsAspirin 100 mg daily100 mg/dPhase III, RCTJuly 2007January 2014Any composite outcome of MI, stroke or CV death∼5 y
Cancer Prevention Programme Project 3 (CAPP3)In developmentCarriers of a germline mismatch repair gene defect, age 18–60 yearsAspirin100, 300, or 600 mg daily for 5 yearsPhase II/III RCT20122020Lynch syndrome cancerAt least 10 y

Abbreviation: RCT, randomized-controlled trial.